ImmuPharma is one of the leading specialist drug development companies listed on AIM of the LSE
Developing innovative drugs
ImmuPharma PLC is one of the leading specialist drug development companies listed on AIM of the LSE. Our corporate strategy and business model differentiates us from many of our peers.
We have UK, French and Swiss operations and have a formal research collaboration with Europe’s largest fundamental research organization in Europe, the Centre National de la Recherche Scientifique (CNRS). ImmuPharma has received to-date $45 million from a corporate deal with a US pharmaceutical company and a number of grants from French government organisations for three of our drug candidates
We have a partnership-based business model, a small core of full time staff, a low R&D cost base, a strong balance sheet and diversified compounds and pipeline.
ImmuPharma has had loyal and supportive shareholders since its listing on AIM that have supported the Company through its history and has helped finance product development.
Nexia Smith & Williamson Audit Limited
Bircham Dyson Bell LLP
Badertscher Rechtsanwälte AG
McCarter & English, LLP, Connecticut, USA
Cabinet Regimbeau, Paris, France
Grosset-Fournier & Demachy, Paris, France
Under contract with a leading manufacturer in the peptides field
“Over the last year, ImmuPharma has continued to progress Lupuzor™ toward its international Phase 3 trial in conjunction with its partner, Avion Pharmaceuticals. In addition, the Company has been active in repositioning and further developing its key assets in the earlier stage development portfolio, including programmes being run in its wholly-owned subsidiary Ureka Pharma SAS.
With my appointment as CEO, leading ImmuPharma through this next significant period, I am determined, working with the excellent team around me, in building shareholder value by progressing the development and commercialisation of all the key assets in our portfolio.”